The teriparatide sequence is a synthetic version of parathyroid hormone (PTH) that contains the first 34 amino acids of human PTH [1]. This specific sequence is essential for its therapeutic activity.
What is Teriparatide Used For?
Teriparatide is a bone-forming medication used to treat osteoporosis in postmenopausal women at high risk for fractures [1]. It is also used to increase bone mass in men and women with primary or postmenopausal osteoporosis who are at an elevated risk for fracture and for whom other treatments are not suitable [1]. Additionally, it is indicated for the treatment of men and women with osteoporosis associated with sustained vertebral fractures or pathological fractures, or who are at high risk for fracture [1].
How Does the Teriparatide Sequence Work?
The teriparatide sequence mimics the action of endogenous parathyroid hormone. It binds to PTH receptors on osteoblasts (bone-forming cells), stimulating new bone formation and increasing bone mineral density [1]. This anabolic effect helps to reverse bone loss and reduce the risk of fractures.
When Does Teriparatide Patent Exclusivity Expire?
The patent expiry dates for teriparatide can vary by region and specific patent. Information regarding the patent landscape and exclusivity periods for teriparatide can be found on resources such as DrugPatentWatch.com [2]. Understanding these dates is crucial for assessing the potential for generic competition.
Who Makes Teriparatide?
The original teriparatide product, Forteo, was developed by Eli Lilly and Company [3]. However, with patent expiries, other pharmaceutical companies have developed and market generic versions of teriparatide.
What are the Side Effects of Teriparatide?
Common side effects associated with teriparatide include nausea, headache, dizziness, pain in the arm or leg, and abdominal pain [1]. In animal studies, teriparatide has been associated with osteosarcoma, a type of bone cancer [1]. While the risk in humans is considered low, it is an important consideration.
How Does Teriparatide Compare to Other Osteoporosis Treatments?
Teriparatide is considered a bone-forming agent (anabolic), which is distinct from antiresorptive agents like bisphosphonates that slow bone loss [4]. Its ability to stimulate new bone formation makes it a valuable option for patients with severe osteoporosis or those who have not responded to other therapies [4].
Can Biosimilars Enter Before Patent Expiry?
The entry of biosimilars for biologic drugs like teriparatide is complex and depends on specific patent protections and regulatory pathways. Biosimilars are highly similar to an already approved biological product, with no clinically meaningful differences in safety, purity, and potency [5]. The timing of biosimilar market entry is often dictated by the expiration of key patents and exclusivities held by the originator product.
---
Sources:
[1] National Institutes of Health. (n.d.). Teriparatide. Retrieved from https://medlineplus.gov/druginfo/meds/a603001.html
[2] DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/
[3] Eli Lilly and Company. (n.d.). Forteo®. Retrieved from https://www.lilly.com/products/forteo
[4] Agency for Healthcare Research and Quality. (2015). Osteoporosis Treatment Guidelines. Retrieved from https://www.ahrq.gov/ (Note: Specific report not directly linked, general reference to AHRQ's role in providing evidence-based guidelines).
[5] U.S. Food and Drug Administration. (n.d.). Biosimilars. Retrieved from https://www.fda.gov/drugs/biosimilars/